Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

July 15, 2015

Primary Completion Date

December 22, 2022

Study Completion Date

December 31, 2024

Conditions
Malignant Neoplasm of StomachMalignant Neoplasm of Cardio-esophageal Junction of StomachEpidermal Growth Factor Receptor (EGFR) Protein Overexpression
Interventions
DRUG

Cisplatin

DRUG

5-fluorouracil or Capecitabine

DRUG

Trastuzumab

DRUG

Pertuzumab

PROCEDURE

gastrectomy

D2 gastrectomy

Trial Locations (48)

1211

Hôpitaux Universitaires de Genève - HUG, Geneva

9000

University Hospital Gent, Ghent

13353

Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum, Berlin

13419

North Estonia Medical Centre, Tallinn

14068

Hallym University Sacred Heart Hospital, Seoul

16247

The Catholic University of Korea-St. Vincent's Hospital, Suwon-Si Gyeonggi-do

17007

ICO Girona - Hospital Dr Josep Trueta (Institut Catala d'Oncologia), Girona

20141

Istituto Europeo di Oncologia, Milan

22291

Asklepios Kliniken GmbH - Asklepios Klinik Barmbek, Hamburg

24127

Azienda Ospedaliera Papa Giovanni XXIII, Bergamo

25030

CHRU de Besancon - Hopital Jean Minjoz, Besançon

26789

Onkologische Unter-Ems (Leer-Papenburg-Emden), Leer

28034

Hospital Universitario Ramon y Cajal, Madrid

33075

CHU de Bordeaux - Group Hospitalier Sud - Hopital Haut-Lévêque, Pessac

37075

Universitaetsmedizin Goettingen - Georg-August Universitaet, Göttingen

45136

Kliniken Essen-Mitte - Evang. Huyssens-Stiftung, Essen

46010

Hospital Clinico Universitario De Valencia, Valencia

51092

CHU de Reims - Hôpital Robert Debré, Reims

55101

Johannes Gutenberg Universitaetskliniken - Mainz University Medical Center, Mainz

59037

CHRU de Lille - Hopital Huriez, Lille

74078

SLK-Kliniken Heilbronn GmbH, Heilbronn

81377

Ludwig-Maximilians-Universitaet München - Campus Grosshadern, München

169610

National Cancer Centre Singapore, Singapore

Unknown

Institut Gustave Roussy, Villejuif

Universitaetsklinikum Leipzig, Leipzig

Technische Universität München - Klinikum Rechts der Isar, München

Azienda Ospedaliera Ordine Mauriziano di Torino, Torino

Instituto Portugues de Oncologia de Lisboa Francisco Gentil, Lisbon

Asan Medical Center, Seoul

Gangnam Severance Hospital, Seoul

Hallym University Sacred Heart Hospital, Seoul

Severance Hospital YUCM, Seoul

Severance Hospital, Yonsei University Health System (YUCM), Seoul

Centre Hospitalier Universitaire Vaudois, Lausanne

University College London Hospitals (UCLH) - NHS Foundation Trust, London

The Christie NHS Foundation Trust, Manchester

01307

Universitaetsklinikum Carl Gustav Carus, Dresden

1066 CX

The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam

1081 HV

Academisch Medisch Centrum - UMC Universiteit van Amsterdam - site: VUMC, Amsterdam

0379

Oslo University Hospital - Radiumhospitalet, Oslo

4200-072

Instituto Portugues De Oncologia - Centro Do Porto, Porto

05505

Asan Medical Center, Seoul

135-720

Gangnam Severance Hospital, Seoul

08908

Institut Catala d'Oncologia - ICO L'Hospitalet, L'Hospitalet de Llobregat

08916

ICO Badalona (Institut Catala d'Oncologia) - Hospital Germans Trias i Pujol, Badalona

08035

Hospital Universitari Vall d'Hebron - Institut Oncologia, Barcelona

B15 2TH

University Hospitals Birmingham NHS - UHB-Queen Elisabeth MC, Birmingham

SM2 5PT

Royal Marsden Hospital - site: Sutton, Surrey, Sutton

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT02205047 - Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma | Biotech Hunter | Biotech Hunter